| ISPC 0.1365 17.17% | CTNT 0.0953 -40.73% | BYND 0.8226 5.19% | YXT 0.496 34.05% | TZA 5.08 -6.45% | EFOI 6.49 210.53% | TSLL 13.9 6.35% | NVDA 201.68 1.68% | BITO 10.63 2.71% | NFLX 97.31 -9.72% | INTC 68.5 0.00% | ZSPC 0.0536 -38.46% | TQQQ 58.59 3.83% | SOXS 18.87 -6.95% | TSLA 400.62 3.01% | XLE 55.02 -2.76% | AMC 1.86 15.53% | SCO 8.47 9.72% | PLUG 2.78 -2.80% | BMNG 1.6 4.58% | IBIT 43.94 2.83% | AAL 12.78 4.16% | BZAI 2.52 45.66% | CRML 12.56 35.49% | SOFI 19.43 2.10% | HIVE 2.51 14.87% | GRAB 4.21 4.73% | SPY 710.14 1.21% | SQQQ 56.39 -3.79% | SOXL 94.68 7.14% | SMR 12.65 10.87% | BMNR 22.95 2.27% | SNAP 6.03 0.17% | UCAR 1.49 29.57% | HIMS 28.82 6.78% | LZMH 0.1736 -84.07% | HYG 80.65 0.37% | DRIP 5.25 9.83% | ONDS 10 -1.96% | DVLT 0.758 -9.49% | AAPL 270.23 2.59% | QQQ 648.85 1.31% | MARA 11.6 0.43% | MSTR 166.52 11.80% | AMZN 250.56 0.34% | PLTR 146.39 2.54% | SPDN 9.13 -1.19% | PBM 7.6 29.47% | IONQ 46.09 3.16% | MSFT 422.79 0.60%

HCA Healthcare's Anticipated Quarterly Earnings: A Deep Dive

HCA Healthcare (NYSE:HCA) is a prominent player in the healthcare sector, providing a wide range of medical services across its network of hospitals and healthcare facilities. As the company prepares to release its quarterly earnings on July 25, 2025, investors and analysts are keenly observing the anticipated financial performance. Wall Street analysts estimate earnings per share (EPS) to be $6.19, with projected revenues of approximately $18.5 billion.

The Zacks Consensus Estimate, however, forecasts a slightly lower EPS of $6.14, reflecting an 11.6% increase from the previous year. Revenues are expected to reach $18.46 billion, marking a 5.5% rise compared to the same quarter last year. Despite a minor downward revision of 0.3% in the consensus EPS estimate over the past 30 days, the earnings estimate has remained stable over the past week, indicating confidence in HCA's projected growth.

HCA's financial metrics provide further insight into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 15.15, suggesting how the market values its earnings. Its price-to-sales ratio stands at about 1.18, indicating the amount investors are willing to pay per dollar of sales. Additionally, HCA's enterprise value to sales ratio is around 1.81, reflecting the company's total valuation relative to its sales.

The company's enterprise value to operating cash flow ratio is approximately 13.39, highlighting its valuation in relation to cash flow from operations. HCA's earnings yield is about 6.60%, providing insight into the return on investment. Notably, the company's debt-to-equity ratio is negative at -13.20, which may suggest a unique financial structure or accounting approach. HCA maintains a current ratio of approximately 1.19, indicating its ability to cover short-term liabilities with short-term assets.

As HCA prepares to report its second-quarter 2025 earnings, the market is closely watching to see if the company will exceed expectations. A positive earnings surprise could boost the stock's price, while failing to meet estimates might lead to a decline. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.

Published on: July 24, 2025